1. Introduction
===============

BVDV belongs to the genus *Pestivirus* of the family *Flaviviridae*, which contains two other genera: *Flavivirus* and *Hepacivirus* ([@bib6]). The genome of BVDV consists of a positive, single-stranded RNA molecule of ∼12.3 kb. Reverse genetics of BVDV has been accomplished by construction of full length cDNA clones following the procedures initially developed by [@bib11] for regeneration of the infectious sindbis virus. Using this strategy, infectious cDNA clones were generated for several pestiviruses and flaviviruses ([@bib1], [@bib3], [@bib7], [@bib8], [@bib9], [@bib12]).

The instability of bacterial plasmid vectors harboring full length cDNA of BVDV have been minimized to levels that allowed the generation of infectious viruses using low-copy number plasmids as backbones. However, this reverse genetics system was not highly reliable since mutations were still observed in BVDV cDNA clones when propagated in bacteria after only a few generations ([@bib7], [@bib8]; our own observation). In an attempt to avoid this problem, a second strategy was used to generate a full length cDNA fragment by *in vitro* ligation by which [@bib10] generated infectious yellow fever virus. By this strategy, a reverse genetics system was developed for flavivirus ([@bib14]) and coronaviruses ([@bib15], [@bib17], [@bib16]). However, it was noted that this strategy decreased the quantity of full length viral cDNA template, so that only low transfection efficiency could be achieved in cultured cells ([@bib15], [@bib17], [@bib16]).

In this study, an improved reverse genetics system of BVDV was developed. Using a single-copy number BAC plasmid as vector and BVDV strain SD1 ([@bib4]), the instability problem of the full length cDNA clone of BVDV in bacteria was resolved and efficient generation of infectious virus was observed.

2. Materials and methods
========================

2.1. Cell, viruses, plasmids, and bacteria strains
--------------------------------------------------

Madin--Darby bovine kidney cells (MDBK) were cultured in Dulbecco\'s modified eagles medium (DMEM) (Fisher Scientific, Pittsburgh, PA) supplemented with 10% heat-inactivated equine serum, 2 μM [l]{.smallcaps}-glutamine, 200 U/ml of penicillin, and 0.2 mg/ml of streptomycin. NCP SD1 strain of BVDV was described previously ([@bib4]). Recombinant BVDV BSD1 and BAC plasmid pBAS were constructed as described below. pACXF, containing nt 1--4,209 of the SD1 genome preceded by a T7 promoter sequence and pBADFP, harboring nt 4,210--12,308 of the SD1 genome followed by an SdaI site have been constructed ([@bib5]). *Escherichia coli* SURE cells and XL1-blue were purchased from Stratagene (La Jolla, CA) and strain DH5α was purchased from Promega (Madison, MI).

2.2. Construction of recombinant plasmids
-----------------------------------------

Plasmids were prepared with a QIAprep Spin Miniprep kit or a QIAGEN Plasmid Maxi kit (Qiagen, Valencia, CA) as detailed by the manufacturer. Restriction enzymes were purchased from New England Biolabs (Beverly, MA). Numbering of nucleotides referred to the sequence of the BVDV SD1 genome (GenBank Accession No. M96751).

### 2.2.1. Construction of the BAC plasmid

pBAS was derived by inserting a cloning adaptor between the ApaLI and SfiI sites of pBeloBACII (New England Biolabs). The adaptor was generated by annealing two oligonucleotides, PBELOASP and PBELOASN ([Table 1](#tbl1){ref-type="table"} ). In pBAS, the original SP6 and T7 promoter sequences were removed and two unique sites for XbaI and PacI were introduced with the adaptor insertion and the original XbaI restriction site was also removed by site-directed mutagenesis as described below.Table 1Oligonucleotides used in adaptor construction, site-directed mutagenesis, RT-PCR, and SYBR-green quantitative RT-PCROligonucleotidesNucleotide sequence (5′--3′)Nucleotide position[a](#tbl1fn1){ref-type="table-fn"}Polarity[b](#tbl1fn2){ref-type="table-fn"}PBELOASPTGCACTTAATTAAGCTAGCATGCTAAGCTTCTAGAGGCCTCAGN/A+PBELOASNAGGCCTCTAGAAGCTTAGCATGCTAGCTTAATTAAGN/A−PBELOXBAPCCATGCTGGTTCGAGAGAAGGTGTTGN/A+PBELOXBANCAACACCTTCTCTCGAACCAGCATGGN/A−BVD424TGCCGTCACTGCCAGTTA424--442+BVD754CAAACAAAAACCCGTCGG736--754−BVD6891AAGACTTGCCGGCCGCTG6891--6909+BVD7920GCGCTGGTGGCATAGGGG7902--7920−BVD8905TACTGGGGTCGGGTTCCG8905--8923+BVD9450GGCCTCGCGTCCTTGTTG9432--9450−BVD9985GGTGTTACGGTGCCCGCC9985--10003+BVD11155ACTTGTGTCTGGCTGGCC11137--11155−BVD12043AAAGGTCCTGCTCATGGC12043--12061+SD1-SdaI-PacIAGTTAATTAACCTGCAGGGGGCTGTTAGAGG12294--12308−[^1][^2][^3]

### 2.2.2. Construction of a full length cDNA clone of BVDV strain SD1

Using standard recombinant DNA techniques, the 4.2 kb XbaI-FseI fragment of pACXF, the 8.1 kb FseI-PacI fragment of pBADFP, and the 7.0 kb XbaI-PacI vector of pBAS were ligated by three-way ligation at 16 °C overnight and a full length cDNA clone, pBSD1, was obtained ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Diagram of BAC cDNA clone pBSD1, including restriction sites for subcloning, sequences surrounding engineered run-off and transcription initiation sites, and introduced genetic markers. The genome of BVDV SD1 is 12,308 nt in length including a 5′-untranslated region (UTR) of 385 nt, a large ORF of 11,697 nt, and a 3′-UTR of 226 nt. pBSD1 with the SD1 cDNA insertion and viral protein positions in the viral polyprotein sequence are indicated approximately to scale. The additional inserted sequences shown below the bar include: the T7 promoter sequence (lowercase, underlined), the T7 transcription start site (arrow), the 5′- and 3′- terminal SD1 cDNA sequences (positive sense, uppercase), engineered run-off restriction site of SdaI (bold, uppercase, underlined), and subcloning restriction sites of XbaI, PacI, and FseI (bold, uppercase, italic). The position of the five silent point mutations employed as genetic markers are indicated noting nucleotide position: T7575C, G7882C, G9022A, A10192G, and A12264G.

2.3. Nucleotide sequencing and site-directed mutagenesis
--------------------------------------------------------

Nucleotide sequencing was performed in the Auburn university genomics and sequencing laboratory using a Templiphi DNA sequencing template Application kit (Amersham Biosciences, Piscataway, NJ). Nucleotides were read by an ABI3100 genetic analyzer (Applied Biosystems, Foster City, CA) and the sequences were analyzed using the DNAman program (Lynnon Cooperation, Que., Canada). Point mutations were generated by a Quickchange site-directed mutagenesis kit (Stratagene) and primer pair PBELOXBAP and PBELOXBAN ([Table 1](#tbl1){ref-type="table"}) as detailed by the manufacturer.

2.4. Determination of the stability of pBSD1 in bacteria
--------------------------------------------------------

The stability of pBSD1 in bacteria was determined by nucleotide sequencing of the progeny plasmids. Three *E. coli* strains (SURE cells, XL1-blue, and DH5α) were transformed with pBSD1 by electroporation at 25 μF, 2.5 kV, and 200 Ω with a Gene Pulser unit (Bio-Rad, Hercules, CA) as described by the manufacturer. After incubation at 37 °C for 1 h with shaking at 275 rpm, cells were spread on LB plates containing 30 μg/ml cloramphenical followed by incubation for 16 h at either 37 °C or 28 °C. The clones were passaged continuously at either 37 °C or 28 °C and progeny plasmids from passage 5 and 10 were sequenced. Each passage was considered to represent approximately 24 generations of the bacterial host.

2.5. Regeneration of recombinant virus
--------------------------------------

*In vitro* transcription was performed with a MEGAscript T7 kit (Ambion, Austin, TX) and the transcripts obtained were analyzed by denaturing agarose gel electrophoresis, quantified by a spectrophotometer, and transfected into MDBK cells with a Gene Pulser unit (Bio-Rad) as described previously ([@bib7]). The transfected cells were incubated at 37 °C for 72 h and the virus was recovered by three cycles of freeze--thaw and identified by focus forming assay as shown below. After five passages in MDBK cells, the recovered virus was titrated and saved as working virus stock.

2.6. Focus forming assay
------------------------

Focus forming assay was performed to identify the virus generation and determine the virus titers. In detail, the virus-infected MDBK cells were incubated for 72 h in 6-well plates (Corning, Corning, NY), washed once with PBS, fixed with 7% formaldehyde for 15 min, and dried for 1.5 h all at room temperature (RT). The cells were incubated for 20 min at 37 °C with bovine polyclonal antiserum B224 (1/350 dilution in PBS-0.25% Triton X-100), washed twice with PBS, and incubated for 20 min at 37 °C with peroxidase-conjugated goat anti-bovine IgG (1/300 dilution in PBS-0.25% Triton X-100). The cells were washed twice with PBS and incubated with peroxidase substrate (Zymed laboratories, South San Francisco, CA) as described by the manufacturer. Viral foci were viewed with a Leica light microscopy (Leica Microsystems Inc. Bannockburn, IL) and recorded with a Canon Powershot A80 digital camera (Canon USA Inc, Lake Success, NY).

2.7. Characterization of the rescued virus
------------------------------------------

Infection of MDBK cells with viruses was performed at a multiplicity of infection (MOI) of 1.0 focus forming unit (FFU)/cell. Transfection efficiency of the *in vitro* transcripts, virus titer, and viral growth kinetics were determined by focus forming assay as detailed previously ([@bib7], [@bib5]).

2.8. Verification of the genetic markers in the recombinant viral genome
------------------------------------------------------------------------

Total cellular RNA were extracted from BSD1-infected MDBK cells using a S.N.A.P total RNA isolation kit (Invitrogen, Carlsbad, CA) as detailed by the manufacturer. RT-PCR was performed using a Superscript™ one-step RT-PCR kit (Invitrogen) as described by the manufacturer. The RT step was performed for 1 h at 42 °C, cDNA was denatured for 2 min at 95 °C and amplified by PCR for 45 cycles at 95 °C for 1 min, 56 °C for 45 s, and 72 °C for 2 min. The PCR products were purified using a QIAquick PCR purification kit (Qiagen) as described by the manufacturer and sequenced for detection of the genetic markers or adaptive mutations in the recombinant viral genome.

2.9. Viral protein quantitation
-------------------------------

Quantitation of the BVDV E2 protein expression was performed by flow cytometry. Virus-infected MDBK cells (1 × 10^5^) were collected at 60 h p.i., washed twice with PBS, and fixed with 4% paraformaldehyde/PBS for 30 min. Cells were washed twice with PBS and immunofluorescently stained with primary mouse anti-E2 monoclonal antibody (Mab) D89 (1:300 dilution, VMRD, Pullman, WA) and secondary Alexa Fluor®680-conjugated rabbit anti-mouse IgG (1:500 dilution, Molecular Probes, Eugene, OR) according to the manufacturers' instructions. Antibody incubations were performed at room temperature. Expression of E2 protein was analyzed with a MoFIo7-color flow cytometer and high-performance cell sorter (Dakocytomation, Fort Collins, Co).

2.10. Viral RNA quantitation
----------------------------

Viral RNA was quantified with SYBR-green quantitative RT-PCR as detailed previously ([@bib13]). The assay was performed in a 50 μl volume containing 2.5 μg of total cellular RNA extracted from the virus-infected MDBK cells at 12, 36, and 60 h p.i. 1 μM of forward primer BVD424 or reverse sense primer BVD754 ([Table 1](#tbl1){ref-type="table"}) and RT-PCR mix (Qiagen). The RT step was performed at 42 °C for 1 h followed by 95 °C for 10 min. Complementary primers were added and the PCR reaction performed for 45 cycles of 95 °C for 1 min, 57 °C for 45 s, and 72 °C for 1 min.

3. Results
==========

3.1. Construction of a stable full-length BAC cDNA clone of BVDV SD1
--------------------------------------------------------------------

A cDNA clone, pBSD1, was constructed from the NCP BVDV SD1 strain using pBAS as a backbone, which was derived from the single-copy number BAC plasmid pBeloBACII. pBSD1 had the following features: an artificially introduced T7 promoter sequence immediately upstream of the SD1 genome for *in vitro* transcription, an engineered SdaI restriction site immediately downstream of the SD1 genome for template linearization, and five artificially introduced silent point mutations in the viral genome as genetic markers ([Fig. 1](#fig1){ref-type="fig"}). This construct allows generation of infectious viral cRNA by *in vitro* transcription, containing correct 5′ and 3′ termini of BVDV SD1 genome. Nucleotide sequencing revealed that progeny plasmids of pBSD1 were identical to the initial one in nucleotide sequence even after 10 passages (approximately 240 generations) as evaluated in three different *E. coli* strains and at two incubation temperatures, respectively ([Table 2](#tbl2){ref-type="table"} ).Table 2Stability analysis of the BAC cDNA clone, pBSD1, replicated in three different *E. coli* strains at two incubation temperatures by nucleotide sequencing*E. coli* strains used for transformationIncubation temperature28 °C37 °CP5P10P5P10SURE cells++++XL1-blue++++DH5α++++[^4]

3.2. Regeneration of molecularly cloned virus
---------------------------------------------

Two transcripts were synthesized independently from SdaI-linearized pBSD1 with T7 RNA polymerase. Both *in vitro* transcripts appeared homologous in size at ∼12.3 kb as expected ([Fig. 2](#fig2){ref-type="fig"}A) and led to the regeneration of infectious viruses after transfection into MDBK cells ([Fig. 2](#fig2){ref-type="fig"}B). *In vitro* transcripts had a high transfection efficiency of 5.0 × 10^5^  FFU/μg RNA in MDBK cells ([@bib7]).Fig. 2Generation of molecularly cloned virus, BSD1, derived from a BAC cDNA clone, pBSD1. (A) Analysis of the *in vitro* transcripts synthesized from pBSD1 by denaturing agarose gel electrophoresis. Lane M shows molecular weight of the 1 kb RNA ladder (size indicated on the left), Lanes 1 and 2 show two independently-generated RNA molecules derived from pBSD1 by *in vitro* transcription with an expected size of ∼12.3 kb. (B) Detection of infectious virus. MDBK cells were treated with the supernatant from transfected cells or mock- or wt SD1-infected MDBK cells (set as negative and positive controls, respectively). Viral foci were visualized by immunoperoxidase staining at 72 h p.i.

Virus titer of the recovered virus termed as BSD1 was determined as 4.2 × 10^2^  FFU/ml at passage 0 and rapidly increased to 2.3 × 10^7^  FFU/ml after 5 passages in MDBK cells ([Fig. 3](#fig3){ref-type="fig"}A). The growth kinetics of BSD1 was similar to that of wild-type (wt) SD1 and both viruses approached a peak yield at 60 h p.i. at either a high MOI of 1.0 FFU/cell or a low MOI of 0.1 FFU/cell ([Fig. 3](#fig3){ref-type="fig"}B).Fig. 3Amplification of the recovered virus in MDBK cells. (A) BSD1 at passage 0 was passaged 5 more times in MDBK cells and the virus titer of each passage determined by focus forming assay. Mock-infected MDBK cells were analyzed in parallel as negative control. The virus titer curves were plotted as mean values derived from three independent experiments against passage number. (B) and (C) Comparison of viral growth kinetics between BSD1 and wt SD1. MDBK cells were infected with either BSD1 or wt SD1 at an MOI of either 0.1 FFU/cell (B) or 1.0 FFU/cell (C). At the indicated times p.i., viruses were collected by three cycles of freeze--thaw and virus titers determined by focus forming assay. One-step growth curves of viruses were plotted as mean values derived from three independent experiments against time.

3.3. Verification of genetic markers in the viral genome of BSD1
----------------------------------------------------------------

To exclude the possibility that the virus was regenerated via accidental contamination with field or lab-stored BVDV strains, RT-PCR assays and nucleotide sequencing were performed to detect the introduced genetic markers in the BSD1 genome. Results demonstrated the presence of the 5 silent point mutations, including T7575C, G7882C, T9022A, A10912G, and A12264G in the BSD1 genome at passage 5 ([Fig. 4](#fig4){ref-type="fig"} ). To investigate if adaptive mutations had accumulated in the BSD1 genome during viral passage in MDBK cells, the entire BSD1 genome at passage 5 was reverse transcribed. The viral cDNAs obtained were amplified by PCR and sequenced. The results demonstrated that BSD1 retained the original sequence of pBSD1 as engineered (data not shown).Fig. 4Identification of the artificially introduced silent point mutations in the BSD1 genome. RT-PCR of total cellular RNA extracted from BSD1-infected MDBK cells was performed using primer pairs which span the genetic markers in the BSD1 genome. The cDNA products were purified and sequenced directly. Only a portion of the sequencing data containing the silent point mutations is presented: (A) T7575C; (B) G7872C; (C) T9022A; (D) A10912G; and (E) A12264G. The primer pairs used for RT-PCR were: BVD6891 and BVD7920 for panel (A) and (B); BVD8905 and BVD9450 for panel (C); BVD9985 and BVD11155 for panel (D); and BVD12043 and SD1-SdaI-PacI for (E). The silent point mutations are indicated with white nucleotide letters on black in each panel.

3.4. Comparison of viral RNA replication and viral protein expression
---------------------------------------------------------------------

Positive- and negative-sense viral RNAs were quantified within the linear range of the assay and by reference to viral RNA isolated from a virus stock of wt SD1 with a known titer of 1 × 10^6^  FFU/ml through selective usage of antisense primer or sense primer in the RT step of RT-PCR assays. The standard curve was determined with a Ct value (threshold cycles) of 0.9912. BSD1 was comparable to wt SD1 for both positive- and negative-sense viral RNA replication when determined at 12, 36, and 60 h p.i., respectively ([Fig. 5](#fig5){ref-type="fig"}A and B). Using the viral E2 protein as an indicator, viral protein expression was determined by flow cytometry. Both BSD1 and wt SD1 had a mean fluorescence intensity of up to 21.50 that was approximately 20 times higher than background fluorescence of mock-infected MDBK cells, which were labeled with either primary and secondary antibodies or only secondary antibody as negative controls ([Fig. 6](#fig6){ref-type="fig"} ).Fig. 5Viral RNA quantitation of BSD1 with SYBR-green quantitative RT-PCR in a time course analysis. (A) Standard curve of quantitative RT-PCR of viral RNA in infected MDBK cells. Ct values were plotted against the log of a known amount of BVDV strain SD1 (FFU). Quantitation of viral positive RNA (B) and negative RNA (C) strands. For both panels, MDBK cells were infected with BSD1 or wt SD1 as well as mock-infected MDBK cells as a negative control. Cells were harvested at indicated time points, total cellular RNAs were isolated, and viral positive and negative RNA content were determined. Error bars represent the standard deviation for three independent experiments.Fig. 6Comparison of viral E2 protein expression between BSD1 and wt SD1. MDBK cells were infected with BSD1 or wt SD1 as well as mock-infected MDBK cells as negative controls. At 60 h p.i., cells were immunostained and the fluorescence intensity of the cells was determined by flow cytometry at a detection spectrum of 698 nm. E2 protein expression was reflected by mean fluorescence intensity (MFI) of the E2-positive cells and indicated in each panel. (a) Mock-infected MDBK cells; (b) Mock-infected MDBK cells incubated only with secondary antibody; (c) wt SD1-infected MDBK cells; (d) BSD1-infected MDBK cells.

4. Conclusion and discussion
============================

Reverse genetics has provided a powerful tool for investigation of many aspects of the viral life cycle and pathogenesis based on infectious cDNA clones of BVDV. Single-copy number BAC plasmids, such as pBeloBACII, had been employed in stable cloning and expression of large DNAs including viral genomic cDNAs, such as coronaviruses, which possess a RNA genome of ∼30 kb ([@bib2]). The ability of BAC plasmids to contain large cDNA fragments and to propagate easily in bacteria make them useful vectors for cloning of the full length cDNA of BVDV, which possess a genome of ∼12.3 kb. Here, an improved reverse genetics system for BVDV was developed combining two strategies: (1) cloning a full length viral cDNA as a BAC to improve its stability when propagated in bacteria and (2) use of an *in vitro* transcription system for generation of infectious RNAs which provided a high transfection efficiency in cultured cells due to the availability of sufficient BAC cDNA template for *in vitro* transcription. In this study, the cDNA construct results in generation of infectious viral cRNAs harboring correct genomic ends of BVDV SD1. Due to the observation that both 5′ and 3′ termini of BVDV genome play a vital role in determining viral RNA infectivity, this system thus probably can provide viral cRNAs with a similar infectivity as that of BVDV SD1 genome.

*E. coli* strains and the incubation temperatures were two factors which have been shown to affect the stability of full length cDNA clones of BVDV in a low-copy number plasmid backbone ([@bib7], [@bib8]; our own observation). Here, a full length cDNA clone of BVDV strain SD1, termed pBSD1, was constructed in a BAC plasmid derived from a single-copy number BAC plasmid, pBeloBACII, and was demonstrated to be stable when evaluated in three different *E. coli* strains and when incubated at either 28 °C or 37 °C. These results showed that the stability of pBSD1 was independent of the bacterial strains and incubation temperatures employed. As expected, *in vitro* transcribed RNA from the pBSD1 template was homologous with a size of ∼12.3 kb and highly infectious with a transfection efficiency of 5.0 × 10^5^  FFU/μg RNA in MDBK cells. The recovered progeny virus, BSD1, approached a virus titer of 2.3 × 10^7^  FFU/ml, which was comparable to the highest virus titer of wt SD1 and retained the original sequence of pBSD1 as engineered for at least 5 passages in MDBK cells. BSD1 was similar to parental SD1 strain in viral growth kinetics, viral RNA replication, and viral protein expression. Thus, the reverse genetics system described here not only provides a reliable tool for investigation of the life cycle of BVDV but also provides evidence BAC plasmids might be ideal cloning vectors for construction of infectious cDNA clones of other RNA viruses with large genome sizes.
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[^1]: N/A indicates the primers are used for adaptor construction or site-directed mutagenesis.

[^2]: Nucleotide positions are in reference to GenBank Accession No. M96751 for BVDV strain SD1.

[^3]: \+ and − indicate forward and reverse primers, respectively.

[^4]: P5 and P10 represent the 5th and 10th passages of the transformed bacteria strains containing pBSD1, respectively; + represents no mutations were detected in nucleotide sequences of the progeny plasmids of pBSD1.
